ArticleScientific reports2022
Early neurological deterioration after intravenous thrombolysis of anterior vs posterior circulation stroke: a secondary analysis of INTRECIS.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02854592 (Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Risk factors for unexplained early neurological deterioration after intravenous thrombolysis: a meta-analysis.Neurosciences (Riyadh, Saudi Arabia) · 2025Pooled it
- Baseline systolic blood pressure and efficacy of dual antiplatelet in acute ischaemic stroke.Stroke and vascular neurology · 2025Trial
- Early Neurologic Deterioration and Efficacy of Dual Antiplatelet in Anterior Versus Posterior Circulation Stroke.Journal of the American Heart Association · 2025Trial
- Argatroban plus alteplase in posterior versus anterior circulation stroke.Annals of clinical and translational neurology · 2025Trial
- Article
- Residual early neurological deterioration following dual antiplatelet in stroke: post hoc analysis of the ATAMIS trial.Therapeutic advances in neurological disorders · 2026Article
- Development and Validation of a Web-Based Machine Learning Model for Predicting Early Neurological Deterioration Following Stroke Thrombolysis: Multicenter Study.Journal of medical Internet research · 2025Article
- Dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke.Stroke and vascular neurology · 2025Article
- Effect of Nurse's detection of neurological deterioration on the prognosis of patients with acute cerebral infarction.Heliyon · 2024Article
- Risk Factors and Prognosis of Early Neurological Deterioration after Bridging Therapy.Current neurovascular research · 2024Article
- Outcome predictors in anterior and posterior ischemic strokes: a study based on the Iranian SITS registry.Scientific reports · 2023Article
- A nomogram predicts early neurological deterioration after mechanical thrombectomy in patients with ischemic stroke.Frontiers in neurology · 2023Article
- Early blood pressure changes during systemic thrombolysis and its association with unexplained early neurological deterioration in small subcortical infarct.Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
- Malnutrition and the Risk of Early Neurological Deterioration in Elderly Patients with Acute Ischemic Stroke.Neuropsychiatric disease and treatment · 2022Article
- Prognostic nomogram for the outcomes in acute stroke patients with intravenous thrombolysis.Frontiers in neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anterior circulation stroke (ACS) differs from posterior circulation stroke (PCS) in many ways, but it remains unclear whether there is any difference in early neurological deterioration (END) in two stroke territories. We compared post-thrombolytic END between ACS and PCS based on the data from INTRECIS. We screened patients receiving intravenous 0.9 mg/kg alteplase within 4.5 h in the INTRECIS cohort. According to stroke territory, patients were divided into ACS and PCS groups. The primary outcome was incidence of END, which was defined as an increase in NIHSS score ≥ 4 or death within 24 h from baseline. The secondary outcomes were associated factors of END and 90-day modified Rankin Scale (mRS) distribution. Overall, 1194 patients were enrolled in this study: 942 in ACS group and 252 in PCS group. There was no significant difference in the incidence of END between two groups (3.8% vs 5.2%, adjusted p = 0.406). Atrial fibrillation (adjusted p = 0.012) and TOAST classification (adjusted p = 0.009) were associated with END in ACS, while hypertension history (adjusted p = 0.046) and baseline NIHSS score (adjusted p = 0.011) with END in PCS. END was associated with worse outcome on 90-day mRS in ACS and PCS (adjusted p < 0.001). Based on a prospective nationwide cohort, we provided first report for similar incidence, but different risk factors of post-thrombolytic END in ACS vs PCS patients.Trial Registration-URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02854592.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.